Neurofenix has raised US$7 million in Series A funding via a round led by AlbionVC, with additional participation from HTH, InHealth Ventures, and existing investors, according to a company press release.
The release notes that this will enable Neurofenix to build out its product line and invest in US expansion, including funding US clinical trials.
The company’s rehabilitation programme focuses on arm and hand therapy through its NeuroBall platform—which was designed with input from more than 300 therapists and patients, and is personalised to each patient based on their needs and enables them to perform increasingly challenging, repetitive movements to build up strength.
As per the release, advanced sensors detect the smallest of movements so it can be used by impaired patients, while the WiFi-connected app features activities and digital games to motivate patients to use it regularly, and real-time feedback and leaderboards encourage them to continue doing so.
In three separate trials carried out at Brunel University (London, UK) between 2017 and 2021, patients achieved 20 times more movement repetitions at home compared to other methods, the release states, adding that the portable platform can be “taken anywhere”.
The proprietary portal enables remote patient monitoring, proving popular in the USA with occupational therapists who increased trust in digital care delivery during the COVID-19 pandemic, Neurofenix claims.
Guillem Singla Buxarrais, CEO and co-founder of Neurofenix, said: “Over the last six years, we have been developing our patient-centric, sensor-based technology and platform to transform neuro-rehab. This has proven transformative as, previously, patients would not have access to in-person physical or occupational therapy due to insurance, financial, transportation and health barriers.”